Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults (TACKLE)
A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults
Sponsor: AstraZeneca
Listed as NCT04723394, this PHASE3 trial focuses on COVID-19 and remains completed. Sponsored by AstraZeneca, it has been updated 13 times since 2021, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Feb 2023 — Jul 2023 [monthly]
Completed PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
-
Oct 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Mar 2021 — Sep 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Jan 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .